Omega Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Kaan Certel

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.8yrs

Recent management updates

Recent updates

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

Aug 04

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Jul 14

CEO

Kaan Certel

no data

Tenure

Dr. Kaan Certel, Ph D., serves as President, CEO & Director at Omega Therapeutics, Inc. since November 2024 and was its Chief Business Officer since May 2024 until November 2024. Dr. Certel is a recognized...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kaan Certel	President	no data	no data	no data
David Berry	Founder	7.8yrs	US$20.33k	no data
Barbara Chan	Principal Financial Office	less than a year	no data	0.068% $ 29.2k
Jennifer Nelson	Chief Scientific Officer	no data	no data	no data
Eva Stroynowski	Senior Vice President of Investor Relations & Corporate Affairs	less than a year	no data	no data
Anthony Mullin	Chief People Officer	1.8yrs	no data	no data
Charles O'Donnell	VP and Head of Computational Genomics & Data Sciences	3.2yrs	no data	no data
Lisamarie Fahy	Senior Vice President of Clinical Development Operations	less than a year	no data	no data
Joe Newman	Senior Vice President of Early Discovery	less than a year	no data	no data

0.8yrs

Average Tenure

Experienced Management: OMGA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kaan Certel	President	no data	no data	no data
John Mendlein	Independent Director	4.8yrs	US$151.29k	0% $ 0
Christian Schade	Independent Chairman of Board	1.3yrs	US$135.55k	0% $ 0
Richard Young	Independent Director & Scientific Advisor	7.3yrs	US$265.18k	1.34% $ 573.6k
Mary Szela	Independent Director	5.4yrs	US$153.68k	0% $ 0
Rainer Boehm	Independent Director	2.3yrs	US$148.68k	0% $ 0
Rudolf Jaenisch	Scientific Advisor	no data	no data	no data
Richard Kender	Independent Director	less than a year	no data	no data
Elliott Levy	Independent Director	3.7yrs	US$149.19k	0% $ 0
Robert Rosiello	Director	less than a year	no data	no data
Michelle Werner	Independent Director	1.3yrs	US$97.51k	0% $ 0

1.8yrs

Average Tenure

64yo

Average Age

Experienced Board: OMGA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Omega Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Omega Therapeutics, Inc. Announces Chief Executive Officer Changes

High number of new directors

Omega Therapeutics, Inc. Elects Robert L. Rosiello as Class I Director

Omega Therapeutics, Inc. Announces Executive Changes

Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors

Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer

Recent updates

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Omega Therapeutics, Inc. Announces Chief Executive Officer Changes

High number of new directors

Omega Therapeutics, Inc. Elects Robert L. Rosiello as Class I Director

Omega Therapeutics, Inc. Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Omega Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 30%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell Small Cap Completeness Index

Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors

Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer

Consensus revenue estimates increase by 24%

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

New major risk - Revenue and earnings growth

Omega Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control

Consensus revenue estimates increase by 43%

Price target decreased by 9.2% to US$11.20

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?

Omega Therapeutics: The Next Weight Loss Drug Runner

Omega Therapeutics: Starting 2024 With A Bang

Consensus revenue estimates increase by 26%

Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

New minor risk - Market cap size

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial

Price target increased by 8.6% to US$13.40

High number of new directors

Omega Therapeutics, Inc. Announces Board Changes

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Omega Therapeutics Appoints Chris Schade to Its Board of Directors

Price target decreased by 9.0% to US$11.83

Consensus EPS estimates upgraded to US$2.23 loss

Forecast to breakeven in 2025

Price target increased by 14% to US$14.80

Consensus revenue estimates increase by 57%

Board Member notifies of intention to sell stock

Forecast to breakeven in 2025

Price target decreased by 17% to US$13.00

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 62%

Price target increased to US$18.50

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Omega Therapeutics, Inc. Announces First Patient Dosed in Landmark MYCHELANGELO(TM) I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

Omega Therapeutics, Inc. Unveils New Epigenomic Controller Development Candidate Targeting MYC Driven Non-Small Cell Lung Cancer

Omega Therapeutics, Inc. Announces Appointment of Rainer Boehm to its Board of Directors

Consensus forecasts updated

Price target increased to US$20.67

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

High number of new directors

Omega Therapeutics, Inc. Announces U.S. Food and Drug Administration Clearance of IND Application for OTX-2002

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the First Epigenomic Controller, Otx-2002, as A Potential Therapeutic Approach in Hepatocellular Carcinoma At the Esmo 2022 World Congress on Gastrointestinal Cancer

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2500 Value Index

Omega Therapeutics, Inc. Announces Submission of Investigational New Drug Application for Otx-2002

Omega Therapeutics Announces Appoints Joshua Reed as Chief Financial Officer, Effective May 23, 2022

High number of new directors

Omega Therapeutics Inc. Announces Executive Changes

High number of new directors

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure